Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm study of envafolimab monotherapy in advanced solid tumors
CTR20211041Phase 2Active
- Sponsor
- Alphamab Oncology
- Start
- Aug 2021
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab, sponsored by Alphamab Oncology. Started Aug 2021; status: active.
02
Drugs
envafolimab
Beyond the preview
Go deeper on CTR20211041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211041.